Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kinetics.

What Was Tested

Researchers studied C-Peptide in this randomized controlled trial publication.

However, use of these β-cell function indices assumes C-peptide kinetics are not altered by canagliflozin.

C-peptide kinetic parameters, including total clearance (CLtotal ) and renal clearance (CLrenal ), were calculated.

Who Took Part

The study group was 10 participants.

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this C-Peptide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on C-Peptide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with C-Peptide could be set against what happens without it.

Each person switched between C-Peptide and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Biomarkers, C-Peptide, Canagliflozin, Germany, Healthy Volunteers, Hypoglycemic Agents and Insulin-Secreting Cells.

The authors tagged it with the keywords kinetics, sodium glucose co-transporter 2 (SGLT2) inhibitor and β-cell function.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of C-Peptide in 10 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2015 (Clinical pharmacology in drug development), a journal based in United States.

More context: the C-Peptide compound page, all human trials.